Kevin Sheth, MD, FAHA, FCCM, FNCS, FANA, FAAN(Neurology)

Associate Professor of Neurology and of Neurosurgery; Associate Chair for Clinical Research, Department of Neurology; Division Chief, Neurocritical Care and Emergency Neurology; Director, Neuroscience ICU

Research Departments & Organizations


Center for Neuroepidemiology and Clinical Neurological Research

Center for Outcomes Research & Evaluation (CORE)

Office of Cooperative Research

Research Interests

Biomarkers, Pharmacological; Brain Edema; Brain Hemorrhage, Traumatic; Brain Infarction; Infarction, Middle Cerebral Artery; Neurology; Neurosciences; Neurosurgery; Quality of Health Care; Subarachnoid Hemorrhage; Trauma, Nervous System

Research Summary

Dr. Sheth's research focuses on the identification and translation of new therapies for patients with acute neurological injury such as stroke, brain hemorrhage, and trauma. The main focus of his group is to further the understanding of inflammation and swelling after acute central nervous system injury. His group is actively involved in developing new methods, including neuroimaging, to detect and follow brain swelling. He is also involved in leading several national clinical trials testing novel therapies directed at brain swelling. Dr. Sheth also studies medical decision making and prognostication in patients with acute neurological injury.

Specialized Terms: Brain edema; Stroke; Intracranial hemorrhage; Neurocritical Care; Critical care; Prognosis; Biomarkers; Clinical Trials

Extensive Research Description

The central mission of my research program is to 1. Improve our understanding of blood brain barrier injury, inflammation, and swelling after acute central nervous system injury and 2. Translate novel therapies to critically ill neurological patients in the hopes of improving what are all too often devastating outcomes.

For the early part of my career, I have partnered with Marc Simard, a vascular neurosurgeon at the University of Maryland, who discovered a new receptor in the brain, SUR1, expressed on all components of the neurovascular unit. Blockade at the capillary level reduces the formation of the space-occupying edema responsible for cell death. Small molecule-based therapy using the well-known and safe drug glyburide is effective in blocking this channel, thereby significantly reducing edema formation following ischemia.

With the direct purpose of translating this therapy using a novel approach in stroke (prevention of swelling), I have formed a research group working toward solving fundamental gaps in knowledge with the ability to reliably measure brain edema. In order to develop this intermediate endpoint, we have recently validated and published unique neuroimaging measures of brain swelling in patients with large stroke. In addition, we are exploring how novel therapies like glyburide may attenuate serum markers of injury at the blood-brain barrier. Early work in human patients suggests that MMP-9 levels are reduced in patients treated with glyburide, and this observation is associated with decreased swelling and hemorrhagic transformation. We continue to search for new pharmacodynamics markers of injury. Both areas of inquiry leverage existing collaborations with groups at Massachusetts General Hospital, Stanford University, and other institutions as well as groups here at Yale.

Our group has had the privilege of leading several phase II trials of IV glyburide in patients with large hemispheric infarction. GAMES-RP demonstrates that IV glyburide reduces neurological mortality, decreases midline shift, and reduces levels of MMP-9. These results are now to be carried forward in a global phase III study in patients with large stroke.

We continue to use clinical trials as a platform for both delivering improved outcomes to patients and also for returning to the laboratory to better understand mechanisms of disease. Below are some examples from our research group.

INTREPID (Impact of Fever Prevention in Brain Injured Patients) - This is a phase III study of over 1000 ischemic and hemorrhagic stroke patients testing the following hypothesis: does fever prevention, using an advanced cooling device, result in improved neurology outcomes in patients with severe stroke.

Saponimod in Intracerebral HemorrhageĀ - Related to our group's efforts towards characterizing edema formation in acute brain injury, we have partnered with several groups (Fu-Dong Shi - Barrow) to further understand the role of S1P modulation in ICH. S1P is a known target in multiple sclerosis, where via multiple mechanisms of action (prevention of lymphocyte egress, direct neuroprotection), drugs such as fingolimod are used in clinical practice. Recent evidence in several preclinical models of ICH suggests that S1P modulation may be beneficial in ICH. We are conducting a series of laboratory experiments that would support the framework for an early phase clinical trial and collaborating with Novartis to execute a 100 patient multinational multicenter phase II study to further understand the role of S1P modulation on secondary brain injury in ICH.

ASPIRE (Anticoagulation in ICH Survivors for Prevention and Recovery) - As many as 20% of ICH survivors have atrial fibrillation and are at high risk for cardioembolic stroke. However, whether or not anticoagulation may safely result in decreased stroke (ischemic and hemorrhagic) and mortality has never been tested in an adequately powered prospective trial. Several analyses from our group and others suggest that oral anticoagulation can improve outcomes in ICH survivors with AF

In addition, to the clinical trials above, we work with large administrative datasets (CMS, State Medicare), imaging cores, and multicenter observational studies (ERICH) in order to identify and support lines of inquiry that can elucidate improved treatments for patients with acute brain injury. We have also received support from the AHA to further the development and implementation of unique bedside neuroimaging capabilities that will also facilities rapid and effective bedside diagnosis and monitoring of primary and secondary brain injury.

Clinical Trials

Conditions Study Title
Diseases of the Nervous System Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (CHARM)
Diseases of the Nervous System An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
Diseases of the Cardiovascular System Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin (ASTROH)
Diseases of the Nervous System Transforming Acute Stroke Detection through Real Time Neurological Monitoring
Diseases of the Nervous System Impact of Fever Prevention in Brain Injured Patients (INTREPID)
Diseases of the Nervous System, Diseases of the Respiratory Systems SETPOINT 2 Stroke-Related Early Tracheostomy versus Prolonged Orotracheal Intubation in Neurocritical Care Trial 2

Selected Publications

See list of PubMed publications

Edit this profile


Gordon Sze

Contact Info

Kevin Sheth, MD, FAHA, FCCM, FNCS, FANA, FAAN(Neurology)
Mailing Address
NeurologyPO Box 208018
New Haven, CT 06520-8018

Curriculum Vitae